Progyny Approves $200 Million Share Repurchase Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 8 hours ago
0mins
Progyny announced that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock. The program will be funded through available cash balances.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PGNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PGNY
Wall Street analysts forecast PGNY stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 24.880
Low
26.00
Averages
29.75
High
34.00
Current: 24.880
Low
26.00
Averages
29.75
High
34.00
About PGNY
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Progyny Approves $200M Share Repurchase Program
- Share Repurchase Program: Progyny's board has approved a share repurchase program of up to $200 million, which will be funded through available cash balances, aimed at enhancing shareholder value and boosting market confidence.
- Stock Price Reaction: Following the announcement, Progyny's stock rose 1.6% in premarket trading to $25.28, indicating a positive market response to the company's repurchase initiative.
- Future Financial Outlook: Progyny anticipates revenue for 2026 to be between $1.365 billion and $1.405 billion, while adjusted EBITDA is expected to rise to between $232 million and $244 million, showcasing the company's growth potential.
- Strategic Market Implications: By implementing the share repurchase, Progyny not only strengthens its capital structure but may also attract more investor interest, thereby further solidifying its position in the competitive healthcare market.
See More
Progyny Authorized to Repurchase $200 Million in Stock
- Buyback Program Initiated: Progyny has announced authorization to repurchase up to $200 million of its common stock, which will be funded by cash, aimed at enhancing shareholder value and boosting market confidence.
- Positive Market Reaction: Following the buyback announcement, Progyny shares rose 1.04% in pre-market trading on Nasdaq, reaching $25.14 per share, indicating investor optimism regarding the company's future prospects.
- Clear Funding Source: The buyback program will be fully supported by the company's cash reserves, demonstrating Progyny's strong financial position and its ability to effectively utilize capital to reward shareholders.
- Strategic Implications: By implementing the stock repurchase, Progyny not only aims to enhance earnings per share but also seeks to strengthen its market position in the competitive women's health sector, attracting more investor interest.
See More
Latest Wall Street Ratings and Price Target Adjustments
- Micron Price Target Increase: Citigroup raised Micron Technology's price target from $425 to $840, anticipating a 40% increase in DRAM prices in Q2, which will significantly enhance its market competitiveness.
- Jazz Pharmaceuticals Upgrade: UBS upgraded Jazz Pharmaceuticals from Neutral to Buy and raised its price target from $188 to $307, driven by increased confidence in the commercial potential of its cancer drug Ziihera, which is expected to boost company performance.
- Nvidia Price Target Boost: HSBC raised Nvidia's price target from $295 to $325, expecting the company to exceed market expectations in its upcoming earnings report, further enhancing its profitability.
- Costco Price Target Increase: Oppenheimer raised Costco's price target from $1,100 to $1,160, believing that its defensive characteristics and superior value proposition will continue to drive market share growth, with potential catalysts for a special dividend or stock split.
See More
Progyny Q1 Earnings Beat Expectations, Shares Surge 17.5%
- Earnings Surprise: Progyny reported adjusted earnings of $0.50 per share for Q1 2026, surpassing analyst expectations of $0.44, indicating strong profitability and boosting market confidence in future performance.
- Revenue Growth: The company achieved a 1.4% year-over-year revenue increase to $328.5 million in Q1, exceeding Wall Street forecasts, which highlights its ongoing expansion in the fertility benefits market and stable customer demand.
- Optimistic Outlook: Progyny provided a revenue guidance midpoint of $348.5 million for Q2, above analyst estimates, and raised its full-year revenue and EBITDA forecasts, reflecting confidence in future business growth.
- Significant Market Reaction: Following the earnings report, Progyny's shares surged 17.5%, demonstrating a positive investor response to the company's performance and outlook, despite a 12.8% decline year-to-date, indicating lingering concerns about future growth.
See More
U.S. Proposes New Legal Pathway for Fertility Benefits
- New Legal Pathway: The U.S. government proposes allowing employers to offer fertility benefits outside standard health insurance plans, with a lifetime cap of $120K starting after 2028, aimed at enhancing employee reproductive health coverage.
- Fertility Treatments Category: Under the proposed rule, the U.S. Department of Labor will categorize fertility treatments as limited excepted benefits, exempting them from certain components of the Affordable Care Act and simplifying the process for employers to provide these benefits.
- Policy Background: This initiative builds on an executive order from President Trump in February aimed at expanding access to fertility services, particularly in vitro fertilization, which can cost between $12,000 and $25,000 per cycle, highlighting the government's focus on reproductive health issues.
- Market Reaction: Shares of fertility benefits provider Progyny (PGNY) rose ahead of the announcement, with projected 2026 revenues of $1.365B to $1.405B and adjusted EBITDA expectations of $232M to $244M, reflecting optimistic market sentiment regarding the demand for fertility benefits.
See More
Progyny CEO and CFO to Participate in BofA Health Conference
- Executive Participation: Progyny's CEO Pete Anevski and CFO Mark Livingston will participate in the BofA Securities 2026 Health Care Conference on May 12, 2026, highlighting the company's leadership in women's health and family building solutions.
- Live Audiocast Available: The conference will take place at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time, with a live audiocast and replay accessible on Progyny's website, ensuring timely information for investors and stakeholders.
- Industry Recognition: Progyny has been recognized as a TIME100 Most Influential Company, CNBC Disruptor 50, and Modern Healthcare's Best Places to Work, underscoring its innovation and market impact in the women's health sector, further solidifying its leadership position in the industry.
- Comprehensive Solution Benefits: Progyny's benefits solutions empower patients with personalized support, education, and digital tools, driving optimal clinical outcomes while reducing healthcare costs, demonstrating strategic significance in enhancing patient experience and optimizing employer benefits.
See More
Progyny Approves $200M Share Repurchase Program
- Share Repurchase Program: Progyny's board has approved a share repurchase program of up to $200 million, which will be funded through available cash balances, aimed at enhancing shareholder value and boosting market confidence.
- Stock Price Reaction: Following the announcement, Progyny's stock rose 1.6% in premarket trading to $25.28, indicating a positive market response to the company's repurchase initiative.
- Future Financial Outlook: Progyny anticipates revenue for 2026 to be between $1.365 billion and $1.405 billion, while adjusted EBITDA is expected to rise to between $232 million and $244 million, showcasing the company's growth potential.
- Strategic Market Implications: By implementing the share repurchase, Progyny not only strengthens its capital structure but may also attract more investor interest, thereby further solidifying its position in the competitive healthcare market.
See More
Progyny Authorized to Repurchase $200 Million in Stock
- Buyback Program Initiated: Progyny has announced authorization to repurchase up to $200 million of its common stock, which will be funded by cash, aimed at enhancing shareholder value and boosting market confidence.
- Positive Market Reaction: Following the buyback announcement, Progyny shares rose 1.04% in pre-market trading on Nasdaq, reaching $25.14 per share, indicating investor optimism regarding the company's future prospects.
- Clear Funding Source: The buyback program will be fully supported by the company's cash reserves, demonstrating Progyny's strong financial position and its ability to effectively utilize capital to reward shareholders.
- Strategic Implications: By implementing the stock repurchase, Progyny not only aims to enhance earnings per share but also seeks to strengthen its market position in the competitive women's health sector, attracting more investor interest.
See More
Latest Wall Street Ratings and Price Target Adjustments
- Micron Price Target Increase: Citigroup raised Micron Technology's price target from $425 to $840, anticipating a 40% increase in DRAM prices in Q2, which will significantly enhance its market competitiveness.
- Jazz Pharmaceuticals Upgrade: UBS upgraded Jazz Pharmaceuticals from Neutral to Buy and raised its price target from $188 to $307, driven by increased confidence in the commercial potential of its cancer drug Ziihera, which is expected to boost company performance.
- Nvidia Price Target Boost: HSBC raised Nvidia's price target from $295 to $325, expecting the company to exceed market expectations in its upcoming earnings report, further enhancing its profitability.
- Costco Price Target Increase: Oppenheimer raised Costco's price target from $1,100 to $1,160, believing that its defensive characteristics and superior value proposition will continue to drive market share growth, with potential catalysts for a special dividend or stock split.
See More
Progyny Q1 Earnings Beat Expectations, Shares Surge 17.5%
- Earnings Surprise: Progyny reported adjusted earnings of $0.50 per share for Q1 2026, surpassing analyst expectations of $0.44, indicating strong profitability and boosting market confidence in future performance.
- Revenue Growth: The company achieved a 1.4% year-over-year revenue increase to $328.5 million in Q1, exceeding Wall Street forecasts, which highlights its ongoing expansion in the fertility benefits market and stable customer demand.
- Optimistic Outlook: Progyny provided a revenue guidance midpoint of $348.5 million for Q2, above analyst estimates, and raised its full-year revenue and EBITDA forecasts, reflecting confidence in future business growth.
- Significant Market Reaction: Following the earnings report, Progyny's shares surged 17.5%, demonstrating a positive investor response to the company's performance and outlook, despite a 12.8% decline year-to-date, indicating lingering concerns about future growth.
See More
U.S. Proposes New Legal Pathway for Fertility Benefits
- New Legal Pathway: The U.S. government proposes allowing employers to offer fertility benefits outside standard health insurance plans, with a lifetime cap of $120K starting after 2028, aimed at enhancing employee reproductive health coverage.
- Fertility Treatments Category: Under the proposed rule, the U.S. Department of Labor will categorize fertility treatments as limited excepted benefits, exempting them from certain components of the Affordable Care Act and simplifying the process for employers to provide these benefits.
- Policy Background: This initiative builds on an executive order from President Trump in February aimed at expanding access to fertility services, particularly in vitro fertilization, which can cost between $12,000 and $25,000 per cycle, highlighting the government's focus on reproductive health issues.
- Market Reaction: Shares of fertility benefits provider Progyny (PGNY) rose ahead of the announcement, with projected 2026 revenues of $1.365B to $1.405B and adjusted EBITDA expectations of $232M to $244M, reflecting optimistic market sentiment regarding the demand for fertility benefits.
See More
Progyny CEO and CFO to Participate in BofA Health Conference
- Executive Participation: Progyny's CEO Pete Anevski and CFO Mark Livingston will participate in the BofA Securities 2026 Health Care Conference on May 12, 2026, highlighting the company's leadership in women's health and family building solutions.
- Live Audiocast Available: The conference will take place at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time, with a live audiocast and replay accessible on Progyny's website, ensuring timely information for investors and stakeholders.
- Industry Recognition: Progyny has been recognized as a TIME100 Most Influential Company, CNBC Disruptor 50, and Modern Healthcare's Best Places to Work, underscoring its innovation and market impact in the women's health sector, further solidifying its leadership position in the industry.
- Comprehensive Solution Benefits: Progyny's benefits solutions empower patients with personalized support, education, and digital tools, driving optimal clinical outcomes while reducing healthcare costs, demonstrating strategic significance in enhancing patient experience and optimizing employer benefits.
See More
